From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

Inflamm Bowel Dis. 2021 Apr 15;27(5):662-666. doi: 10.1093/ibd/izaa162.

Abstract

Background: We aimed to characterize patients with inflammatory bowel disease (IBD) and novel coronavirus disease 2019 (COVID-19).

Methods: We performed a case series of patients with IBD and confirmed or highly suspected COVID-19 to assess rates of severe outcomes.

Results: We identified 83 patients with IBD with confirmed (54%) or highly suspected (46%) COVID-19. The overall hospitalization rate was 6%, generally comprising patients with active Crohn's disease or older men with comorbidities, and 1 patient expired.

Discussion: In this series of patients with IBD, severe outcomes of COVID-19 were rare and comparable to similarly aged individuals in the general population.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; inflammatory bowel disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • COVID-19 / diagnosis*
  • COVID-19 / epidemiology
  • COVID-19 / immunology
  • COVID-19 Testing
  • Female
  • Follow-Up Studies
  • Hospitalization / statistics & numerical data
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / complications*
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / immunology
  • Male
  • Middle Aged
  • New York City / epidemiology
  • Prognosis
  • Risk Factors
  • Severity of Illness Index*
  • Urban Health / statistics & numerical data

Substances

  • Immunosuppressive Agents